The overall lower number of fractures in the denosumab group ( @ ) than in the placebo group ( @ ) was similar in all patient subgroups , including in patients with a bone mineral density T-score of -@ or higher at baseline ( n = @ , HR @ -LSB- @ % CI @-@ -RSB- , p < @ ) and in those with a bone mineral density T-score of less than -@ already at baseline ( n = @ , HR @ -LSB- @ % CI @-@ -RSB- , p = @ ) .